BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)
Status:
Withdrawn
Trial end date:
2020-01-07
Target enrollment:
Participant gender:
Summary
The main objective of this study is to assess the safety, tolerability and pharmacokinetics
of orally administered BI 705564 in patients with systemic lupus erythematosus